Chloe Kent
Senior Reporter
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
Hyloris Announces Approval Of Condylox First Generic
Hyloris has received US approval for its generic podofilox gel, previously referred to as HY-016.
Numerous US Approvals Received By Lupin Following 278% Quarterly Profits Raise
Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.
Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3
Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.
Supplier Shortages To Benefit Amphastar For Many Quarters To Come
Amphastar management has assured stakeholders that it will continue to benefit from competitor shortages for the foreseeable future, with chief financial officer Bill Peters noting that the firm has been plugging gaps in the market throughout his near-decade at the company.
ANI Guidance Raise Can’t Stop Stock Price Slump
Stock prices at ANI Pharmaceuticals dropped 14.8% following its Q3 results announcement, despite a guidance raise from the company, after it noted that competitor supply disruptions seemed to be easing off.
Inflation And Local Currency Depreciation Drag Down Beximco’s Bottom Line
Rising inflation and the depreciation of the Bangladeshi taka have taken their toll on Beximco’s profits even as revenue has continued to rise at the firm.